[ET Net News Agency, 4 January 2022] CStone Pharmaceuticals (02616) said the
investigational new drug (IND) application of lorlatinib for the treatment of c-ros
oncogene 1 (ROS1)-positive advanced non-small cell lung cancer (NSCLC) has been approved
by the National Medical Products Administration (NMPA) of China. This is the first pivotal
study of lorlatinib for the treatment of ROS1-positive NSCLC in the world.
Lorlatinib is approved globally in over 50 countries for metastatic anaplastic lymphoma
kinase (ALK)-positive NSCLC in adults. (RC)